Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
7 Results for "
SARS-CoV-2 RdRp-IN-1
" in MedChemExpress (MCE) Product Catalog:
Products (7)
7 Results for "SARS-CoV-2 RdRp-IN-1" in MCE Product Catalog:
Cat. No.: HY-173134
SARS-CoV-2 RdRp-IN-1 (Compound PAP-2) is a potent SARS-CoV-2 RdRp inhibitor, with an EC50 of 1.11 μM. SARS-CoV-2 RdRp-IN-1 can bind directly to SARS-CoV-2 RdRp, fully resistance to the exoribonuclease (ExoN) and exhibit broad spectrum anti-CoV activities [1].
Cat. No.: HY-13247
CAS No.: 1071517-39-9
Synonyms: ANA598
Target:
Research Areas:
Setrobuvir (ANA598) is an orally active non-nucleosidic HCV NS5B polymerase inhibitor. ANA-598 inhibits both de novo RNA synthesis and primer extension, with IC50s between 4 and 5 nM. Setrobuvir also shows excellent binding affinity to SARS-CoV-2 RdRp and induces RdRp inhibition [2].
Cat. No.: HY-162111
Target:
Research Areas:
SARS-CoV-2-IN-73 (compound 4) is a SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) blocker .
Cat. No.: HY-157022
CAS No.: 2997784-47-9
SARS-CoV-2-IN-67 (Compound 16), a vitamin K derivatives, has anti-SARS-CoV-2 activity (EC50: 64.8 μM in VeroE6/TMPRSS2 cells). SARS-CoV-2-IN-67 inhibits SARS-CoV-2 RdRp activity .
Cat. No.: HY-179283
PROTAC SARS-CoV-2 RdRp Degrader-1 (PROTAC 10) is a SARS-CoV-2 RdRp PROTAC degrader, with a DC50 of 1.97 μM (in infected cells). PROTAC SARS-CoV-2 RdRp Degrader-1 promotes the ubiquitination and degradation of SARS-CoV-2 RdRp. PROTAC SARS-CoV-2 RdRp Degrader-1 can be used in the research of SARS-CoV-2 infection [1].
Cat. No.: HY-178695
Research Areas:
E3 Ligase Ligand-linker Conjugate 216 is a conjugate of an E3 ligase CRBN ligand and a linker. E3 Ligase Ligand-linker Conjugate 216 can be used to synthesize PROTAC SARS-CoV-2 RdRp Degrader-1 (HY-179283). PROTAC SARS-CoV-2 RdRp Degrader-1 is a SARS-CoV-2 RdRp PROTAC degrader [1].
Cat. No.: HY-180673
Target:
Research Areas:
Mpro/RdRp-IN-1 (Compound 1) is a dual-target inhibitor against SARS-CoV-2, targeting RdRp (EC50 = 25.45) and Mpro (IC50 = 125.4 μM). Mpro/RdRp-IN-1 exhibits EC₅₀ for HCoV-OC43 of 4.79 μM, and the selectivity index (SI) is 10.89. Mpro/RdRp-IN-1 can be used for studying SARS-CoV-2 and HCoV-OC43 infections [1].
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
